Zhejiang Starry Pharmaceutical Co.,Ltd.
SHH: 603520.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Weiyi Shen
- Employees
- 1,845
- Headquarters
- Xianju, China
- IPO year
- 2016
- Market cap
- CN¥5.2B
- Website
- https://www.starrypharm.com
Loading 603520…
Loading profile data…Frequently asked questions about 603520
What does Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) do?
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine,...
Where does 603520.SS trade?
Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) trades on the Shanghai Stock Exchange.
What sector is 603520.SS in?
Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Zhejiang Starry Pharmaceutical Co.,Ltd.?
Weiyi Shen is the chief executive officer of Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS).
Where is Zhejiang Starry Pharmaceutical Co.,Ltd. headquartered?
Zhejiang Starry Pharmaceutical Co.,Ltd. is headquartered in China.
Does 603520.SS pay a dividend?
Yes — Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) paid a trailing twelve-month dividend of CNY 0.15 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 603520.SS go public?
Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) completed its initial public offering in 2016.